MedTrace Logo

Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment

NCT05171972 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2026-05-06

No results posted yet for this study

Summary

In this study the investigators wish to test the hypothesis that the repertoire of solutes secreted by leukocytes isolated from patients with relapsing-remitting forms of Multiple Sclerosis (MS) following 6 months of treatment with Ofatumumab (Kesimpta®) will be less toxic to mouse-derived oligodendrocyte lineage cells, grown in a dish, than solutes secreted by the same leukocyte populations prior to treatment with Ofatumumab.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

Ofatumumab

This investigator-initiated study will be carried out secondary to the discussion of treatment with Ofatumumab and thus our study will not influence or impact the determination of the suitability for candidates to commence therapy with Ofatumumab. This decision will be made by the patient's physician as part of the patient's standard care, and will occur independently of this study. Patients to be enrolled in this longitudinal study will only be asked if they would like to take part if their clinician independently chooses Ofatumumab as a treatment option.

Sponsors & Collaborators

Principal Investigators

  • Eve Kelland, Ph.D. · University of Southern California

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-29
Primary Completion
2025-06-30
Completion
2025-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05171972 on ClinicalTrials.gov